Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Humacyte (HUMA) Other Non-Current Liabilities (2024 - 2025)

Humacyte has reported Other Non-Current Liabilities over the past 2 years, most recently at $11.5 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $11.5 million for Q4 2025, down 83.81% from a year ago — trailing twelve months through Dec 2025 was $11.5 million (down 83.81% YoY), and the annual figure for FY2025 was $11.5 million, down 83.81%.
  • Other Non-Current Liabilities for Q4 2025 was $11.5 million at Humacyte, up from $289000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for HUMA hit a ceiling of $76.6 million in Q3 2024 and a floor of $289000.0 in Q3 2025.